Rationale for the use of metronomic chemotherapy in gastrointestinal cancer

References

• Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer. 2005 Jul;5(7):516–525.
   PubMed Web of Science ®Google Scholar
• Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004 Jun;4(6):423–436.
   PubMed Web of Science ®Google Scholar
• Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000 Apr;105(8):R15–R24.
   PubMed Web of Science ®Google Scholar
• Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000 Apr;60(7):1878–1886.
   PubMed Web of Science ®Google Scholar
• Lau DH, Xue L, Young LJ, et al. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radioph. 1999 Feb;14(1):31–36.
   PubMed Web of Science ®Google Scholar
• Lee K, Qian DZ, Rey S, et al. Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proc Natl Acad Sci U S A. 2009 Feb;106(7):2353–2358.
   PubMed Web of Science ®Google Scholar
• Shi H, Jiang J, Ji J, et al. Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer. Cancer Lett. 2014 Jul;349(2):128–135.
   PubMed Web of Science ®Google Scholar
• Iwamoto H, Torimura T, Nakamura T, et al. Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. Neoplasia. 2011 Mar;13(3):187–197.
   PubMed Web of Science ®Google Scholar
• Bocci G, Francia G, Man S, et al. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A. 2003 Oct;100(22):12917–12922.
   PubMed Web of Science ®Google Scholar
• Murakami H, Ogata Y, Akagi Y, et al. Circulating endothelial progenitor cells in metronomic chemotherapy using irinotecan and/or bevacizumab for colon carcinoma: study of their clinical significance. Exp Ther Med. 2011 Jul;2(4):595–600.
   PubMed Web of Science ®Google Scholar
• Natale G, Bocci G. Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data. Cancer Lett. 2018 Sep;432:28–37.
   PubMed Web of Science ®Google Scholar
• Shevchenko I, Karakhanova S, Soltek S, et al. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int J Cancer. 2013 Jul;133(1):98–107.
   PubMed Web of Science ®Google Scholar
• Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immu Immunother. 2007 May;56(5):641–648.
   PubMed Web of Science ®Google Scholar
• Tongu M, Harashima N, Monma H, et al. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immu Immunother. 2013 Feb;62(2):383–391.
   PubMed Web of Science ®Google Scholar
• Vincent J, Mignot G, Chalmin F, et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 2010 Apr;70(8):3052–3061.
   PubMed Web of Science ®Google Scholar
• Vives M, Ginestà MM, Gracova K, et al. Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells. Int J Cancer. 2013 Nov;133(10):2464–2472.
   PubMed Web of Science ®Google Scholar
• Orlandi P, Di Desidero T, Salvia G, et al. Metronomic vinorelbine is directly active on non small cell lung cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors. Biochem Pharmacol. 2018;152:327–337.
   PubMed Web of Science ®Google Scholar
• Biziota E, Mavroeidis L, Hatzimichael E, et al. Metronomic chemotherapy: a potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation. Cancer Lett. 2017 Aug;400:243–251.
   PubMed Web of Science ®Google Scholar
• Chen Y-L, Chang M-C, Cheng W-F. Metronomic chemotherapy and immunotherapy in cancer treatment. Cancer Lett. 2017 Aug;400:282–292.
   PubMed Web of Science ®Google Scholar
• André N, Tsai K, Carré M, et al. Metronomic chemotherapy: direct targeting of cancer cells after all? Trends Cancer. 2017 May;3(5):319–325.
   PubMed Web of Science ®Google Scholar
• Young SD, Whissell M, Noble JC, et al. Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res. 2006 May;12(10):3092–3098.
   PubMed Web of Science ®Google Scholar
• Steinbild S, Arends J, Medinger M, et al. Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients – results of a phase II study. Onkologie. 2007 Dec;30(12):629–635.
   PubMedGoogle Scholar
• Lasalvia-Prisco E, Goldschmidt P, Galmarini F, et al. Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies. Med Oncol. 2012 Dec;29(5):3626–3633.
   PubMed Web of Science ®Google Scholar
• Lokich J. Capecitabine: fixed daily dose and continuous (noncyclic) dosing schedule. Cancer Invest. 2004;22(5):713–717.
   PubMed Web of Science ®Google Scholar
• Allegrini G, Di Desidero T, Barletta MT, et al. Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis. 2012 Jun;15(2):275–286.
   PubMed Web of Science ®Google Scholar
• Miger J, Holmqvist A, Sun XF, et al. Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer. Med Oncol. 2014 Mar;31(3):870.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Kitakata H, Yamashita K, et al. Pilot study of low-dose, divided maximum tolerated dose of CPT-11 in 21 consecutive patients with metastatic colorectal or gastric cancer. Surg Today. 2004;34(3):246–250.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar;136(5):E359–E386.
   PubMed Web of Science ®Google Scholar
• Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015 Nov;21(11):1350–1356.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun;350(23):2335–2342.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012 Oct;30(28):3499–3506.
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan;381(9863):303–312.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016 Aug;27(8):1386–1422.
   PubMed Web of Science ®Google Scholar
• Romiti A, Onesti CE, Roberto M, et al. Continuous, low-dose capecitabine for patients with recurrent colorectal cancer. Med Oncol. 2015 Mar;32(3):54.
   PubMed Web of Science ®Google Scholar
• Hagman H, Frödin JE, Berglund Å, et al. A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial. Ann Oncol. 2016 Jan;27(1):140–147.
   PubMed Web of Science ®Google Scholar
• Simkens LH, Van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch colorectal cancer group. Lancet. 2015 May;385(9980):1843–1852.
   PubMed Web of Science ®Google Scholar
• Falcone A, Cremolini C, Loupakis F, et al. FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): the phase II randomized MOMA trial. Ann Oncol. 2016;27(suppl_6):LBA21–LBA21.
   Google Scholar
• Basaki Y, Chikahisa L, Aoyagi K, et al. Gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. Angiogenesis. 2001;4(3):163–173.
   PubMedGoogle Scholar
• Yonekura K, Basaki Y, Chikahisa L, et al. UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice. Clin Cancer Res. 1999 Aug;5(8):2185–2191.
   PubMed Web of Science ®Google Scholar
• Lin PC, Chen WS, Chao TC, et al. Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer. Cancer Chemother Pharmacol. 2007 Aug;60(3):351–356.
   PubMed Web of Science ®Google Scholar
• Huang WY, Ho CL, Lee CC, et al. Oral tegafur-uracil as metronomic therapy following intravenous FOLFOX for stage III colon cancer. PLoS One. 2017;12(3):e0174280.
   PubMed Web of Science ®Google Scholar
• Yoshimatsu K, Yokomizo H, Fujimoto T, et al. Pilot study of simplified low-dose S-1 plus CPT-11 as first-line chemotherapy for patients with advanced colorectal cancer. Anticancer Res. 2007 May-Jun;27(3B):1657–1661.
   PubMed Web of Science ®Google Scholar
• Ogata Y, Tanaka T, Akagi Y, et al. Multicenter Phase II study of a new effective S-1 and irinotecan combination schedule in patients with unresectable metastatic or recurrent colorectal cancer. Clin Med Insights Oncol. 2013;7:21–30.
   PubMedGoogle Scholar
• Skof E, Rebersek M, Hlebanja Z, et al. Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC Cancer. 2009;9:120.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2008 Feb;26(4):689–690.
   PubMed Web of Science ®Google Scholar
• Xu RH, Muro K, Morita S, et al. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2018 May;19(5):660–671.
   PubMed Web of Science ®Google Scholar
• Bocci G, Falcone A, Fioravanti A, et al. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br J Cancer. 2008 May;98(10):1619–1629.
   PubMed Web of Science ®Google Scholar
• Fioravanti A, Canu B, Alì G, et al. Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer. Eur J Pharmacol. 2009 Oct;619(1–3):8–14.
   PubMed Web of Science ®Google Scholar
• Allegrini G, Falcone A, Fioravanti A, et al. A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br J Cancer. 2008 Apr;98(8):1312–1319.
   PubMed Web of Science ®Google Scholar
• Ogata Y, Sasatomi T, Mori S, et al. Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma. Anticancer Res. 2007 Jul-Aug;27(4C):2605–2611.
   PubMed Web of Science ®Google Scholar
• Kamat AA, Kim TJ, Landen CN, et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 2007 Jan;67(1):281–288.
   PubMed Web of Science ®Google Scholar
• Merritt WM, Danes CG, Shahzad MM, et al. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther. 2009 Aug;8(16):1596–1603.
   PubMed Web of Science ®Google Scholar
• Previs RA, Armaiz-Pena GN, Lin YG, et al. Dual metronomic chemotherapy with nab-paclitaxel and topotecan has potent antiangiogenic activity in ovarian cancer. Mol Cancer Ther. 2015 Dec;14(12):2677–2686.
   PubMed Web of Science ®Google Scholar
• Zhang L, Marrano P, Wu B, et al. Combined antitumor therapy with metronomic topotecan and hypoxia-activated prodrug, evofosfamide, in neuroblastoma and rhabdomyosarcoma preclinical models. Clin Cancer Res. 2016 Jun;22(11):2697–2708.
   PubMed Web of Science ®Google Scholar
• Di Desidero T, Xu P, Man S, et al. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer. Oncotarget. 2015 Dec;6(40):42396–42410.
   PubMedGoogle Scholar
• Jedeszko C, Paez-Ribes M, Di Desidero T, et al. Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib. Sci Transl Med. 2015 Apr;7(282):282ra50.
   PubMed Web of Science ®Google Scholar
• Hackl C, Man S, Francia G, et al. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut. 2013 Feb;62(2):259–271.
   PubMed Web of Science ®Google Scholar
• Jiang H, Tao W, Zhang M, et al. Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice. Cancer Invest. 2010 Jan;28(1):74–84.
   PubMed Web of Science ®Google Scholar
• Bocci G, Di Paolo A, Danesi R. The pharmacological bases of the antiangiogenic activity of paclitaxel. Angiogenesis. 2013 Jul;16(3):481–492.
   PubMed Web of Science ®Google Scholar
• Zhang M, Tao W, Pan S, et al. Low-dose metronomic chemotherapy of paclitaxel synergizes with cetuximab to suppress human colon cancer xenografts. Anticancer Drugs. 2009 Jun;20(5):355–363.
   PubMed Web of Science ®Google Scholar
• Ng SS, Sparreboom A, Shaked Y, et al. Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel. Clin Cancer Res. 2006 Jul;12(14 Pt 1):4331–4338.
   PubMed Web of Science ®Google Scholar
• Zhang M, Chen C, Su F, et al. Knockdown of hypoxia-inducible factor 1α improved the efficacy of low-dose metronomic chemotherapy of paclitaxel in human colon cancer xenografts. Technol Cancer Res Treat. 2017 Oct;16(5):609–619.
   PubMed Web of Science ®Google Scholar
• Lv C, Qu H, Zhu W, et al. Low-dose paclitaxel inhibits tumor cell growth by regulating glutaminolysis in colorectal carcinoma cells. Front Pharmacol. 2017;8:244.
   PubMed Web of Science ®Google Scholar
• Polak L, Turk JL. Reversal of immunological tolerance by cyclophosphamide through inhibition of suppressor cell activity. Nature. 1974 Jun;249(458):654–656.
   PubMedGoogle Scholar
• Glode LM, Barqawi A, Crighton F, et al. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer. 2003 Oct;98(8):1643–1648.
   PubMed Web of Science ®Google Scholar
• Daenen LG, Shaked Y, Man S, et al. Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models. Mol Cancer Ther. 2009 Oct;8(10):2872–2881.
   PubMed Web of Science ®Google Scholar
• Scurr M, Pembroke T, Bloom A, et al. Low-dose cyclophosphamide induces antitumor t-cell responses, which associate with survival in metastatic colorectal cancer. Clin Cancer Res. 2017 Nov;23(22):6771–6780.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Hwang J, Magbanua MJ, et al. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013 Oct;109(7):1725–1734.
   PubMed Web of Science ®Google Scholar
• Tang TC, Man S, Lee CR, et al. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. Neoplasia. 2010 Mar;12(3):264–274.
   PubMed Web of Science ®Google Scholar
• Yoshimoto M, Takao S, Hirata M, et al. Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer. Cancer Chemother Pharmacol. 2012 Aug;70(2):331–338.
   PubMed Web of Science ®Google Scholar
• Munoz R, Man S, Shaked Y, et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 2006 Apr;66(7):3386–3391.
   PubMed Web of Science ®Google Scholar
• Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016 Apr;2:16022.
   PubMed Web of Science ®Google Scholar
• Topalovski M, Brekken RA. Matrix control of pancreatic cancer: new insights into fibronectin signaling. Cancer Lett. 2016 Oct;381(1):252–258.
   PubMed Web of Science ®Google Scholar
• Laquente B, Lacasa C, Ginestà MM, et al. Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Mol Cancer Ther. 2008 Mar;7(3):638–647.
   PubMed Web of Science ®Google Scholar
• Cham KK, Baker JH, Takhar KS, et al. Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma. Br J Cancer. 2010 Jun;103(1):52–60.
   PubMed Web of Science ®Google Scholar
• Yapp DT, Wong MQ, Kyle AH, et al. The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth. Angiogenesis. 2016 Apr;19(2):229–244.
   PubMed Web of Science ®Google Scholar
• Tran Cao HS, Bouvet M, Kaushal S, et al. Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer. Mol Cancer Ther. 2010 Jul;9(7):2068–2078.
   PubMed Web of Science ®Google Scholar
• Eichhorn ME, Ischenko I, Luedemann S, et al. Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer. Int J Cancer. 2010 Mar;126(5):1235–1245.
   PubMed Web of Science ®Google Scholar
• Amado RG, Rosen LS, Hecht JR, et al. Low-dose trimetrexate glucuronate and protracted 5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer. Ann Oncol. 2002 Apr;13(4):582–588.
   PubMed Web of Science ®Google Scholar
• Rothman H, Cantrell JE, Lokich J, et al. Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. Mid-Atlantic Onco Pro Study Cancer. 1991 Jul;68(2):264–268.
   Google Scholar
• Ina S, Tani M, Kawai M, et al. Phase 2 trial of oral S-1 combined with low-dose cisplatin for unresectable advanced pancreatic cancer. Anticancer Res. 2008 Jul-Aug;28(4C):2373–2377.
   PubMed Web of Science ®Google Scholar
• Isacoff WH, Reber HA, Bedford R, et al. Low-dose continuous 5-fluorouracil combined with leucovorin, nab-paclitaxel, oxaliplatin, and bevacizumab for patients with advanced pancreatic cancer: a retrospective analysis. Target Oncol. 2018 Jun;13:461–468.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011 May;364(19):1817–1825.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013 Oct;369(18):1691–1703.
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb;364(6):501–513.
   PubMed Web of Science ®Google Scholar
• Chan JA, Stuart K, Earle CC, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol. 2012 Aug;30(24):2963–2968.
   PubMed Web of Science ®Google Scholar
• Chan JA, Faris JE, Murphy JE, et al. Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET). J Clin Oncol. 2017;35(4_suppl):228.
   Web of Science ®Google Scholar
• Teulé A, Casanovas O. Relevance of angiogenesis in neuroendocrine tumors. Target Oncol. 2012 Jun;7(2):93–98.
   PubMed Web of Science ®Google Scholar
• Man S, Bocci G, Francia G, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 2002 May;62(10):2731–2735.
   PubMed Web of Science ®Google Scholar
• Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol. 2005 Feb;23(5):939–952.
   PubMed Web of Science ®Google Scholar
• Bell-McGuinn KM, Garfall AL, Bogyo M, et al. Inhibition of cysteine cathepsin protease activity enhances chemotherapy regimens by decreasing tumor growth and invasiveness in a mouse model of multistage cancer. Cancer Res. 2007 Aug;67(15):7378–7385.
   PubMed Web of Science ®Google Scholar
• Klöppel G. Neuroendocrine neoplasms: dichotomy, origin and classifications. Visc Med. 2017 Oct;33(5):324–330.
   PubMed Web of Science ®Google Scholar
• Brizzi MP, Berruti A, Ferrero A, et al. Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network. BMC Cancer. 2009;9:388.
   PubMed Web of Science ®Google Scholar
• Berruti A, Fazio N, Ferrero A, et al. Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study. BMC Cancer. 2014 Mar;14:184.
   PubMed Web of Science ®Google Scholar
• Bongiovanni A, Riva N, Calpona S, et al. Metronomic capecitabine in gastroenteropancreatic neuroendrocrine tumors: a suitable regimen and review of the literature. Onco Targets Ther. 2014;7:1919–1926.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group. J Clin Oncol. 2006 Nov;24(31):4991–4997.
   PubMed Web of Science ®Google Scholar
• Okines AF, Norman AR, McCloud P, et al. Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer. Ann Oncol. 2009 Sep;20(9):1529–1534.
   PubMed Web of Science ®Google Scholar
• Ohtsu A, Shah MA, Van Cutsem E, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2011 Oct;29(30):3968–3976.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014 Jan;383(9911):31–39.
   PubMed Web of Science ®Google Scholar
• Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014 Oct;15(11):1224–1235.
   PubMed Web of Science ®Google Scholar
• Yuan F, Shi H, Ji J, et al. Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis. Oncol Rep. 2015 Apr;33(4):1753–1762.
   PubMed Web of Science ®Google Scholar
• Wang C, Xi W, Jiang J, et al. Metronomic chemotherapy remodel cancer-associated fibroblasts to decrease chemoresistance of gastric cancer in nude mice. Oncol Lett. 2017 Dec;14(6):7903–7909.
   PubMed Web of Science ®Google Scholar
• Wu H, Xin Y, Zhao J, et al. Metronomic docetaxel chemotherapy inhibits angiogenesis and tumor growth in a gastric cancer model. Cancer Chemother Pharmacol. 2011 Oct;68(4):879–887.
   PubMed Web of Science ®Google Scholar
• Cejka D, Preusser M, Woehrer A, et al. Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo. Cancer Biol Ther. 2008 Sep;7(9):1377–1385.
   PubMed Web of Science ®Google Scholar
• Roberto M, Romiti A, Onesti CE, et al. A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer. Anticancer Drugs. 2016 Feb;27(2):106–111.
   PubMed Web of Science ®Google Scholar
• He S, Shen J, Hong L, et al. Capecitabine “metronomic” chemotherapy for palliative treatment of elderly patients with advanced gastric cancer after fluoropyrimidine-based chemotherapy. Med Oncol. 2012 Mar;29(1):100–106.
   PubMed Web of Science ®Google Scholar
• Yang S, Li S, Yu H, et al. Metronomic chemotherapy with 5-fluorouracil and cisplatin for inoperable malignant bowel obstruction because of peritoneal dissemination from gastric cancer. Curr Oncol. 2016 Jun;23(3):e248–e252.
   PubMed Web of Science ®Google Scholar
• Ilson DH, Wadleigh RG, Leichman LP, et al. Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. Ann Oncol. 2007 May;18(5):898–902.
   PubMed Web of Science ®Google Scholar
• Noronha V, Patil V, Bhosale B, et al. Metronomic weekly paclitaxel in advanced unresectable esophageal cancer. Indian J Cancer. 2013 Apr-Jun;50(2):128–134.
   PubMed Web of Science ®Google Scholar
• Kato K, Tahara M, Hironaka S, et al. A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy. Cancer Chemother Pharmacol. 2011 Jun;67(6):1265–1272.
   PubMed Web of Science ®Google Scholar
• Muto J, Shirabe K, Sugimachi K, et al. Review of angiogenesis in hepatocellular carcinoma. Hepatol Res. 2015 Jan;45(1):1–9.
   PubMed Web of Science ®Google Scholar
• Yoshiji H, Kuriyama S, Noguchi R, et al. Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. Gut. 2005 Dec;54(12):1768–1775.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008 Jul;359(4):378–390.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25–34.
   PubMed Web of Science ®Google Scholar
• Cheng A-L, Finn RS, Qin S, et al. Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol. 2017;35(15_suppl):4001.
   Google Scholar
• Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Jan;389(10064):56–66.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng A-L, et al. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: results from the randomized phase III CELESTIAL trial. J Clin Oncol. 2018;36(4_suppl):207.
   Web of Science ®Google Scholar
• Park ST, Jang JW, Kim GD, et al. Beneficial effect of metronomic chemotherapy on tumor suppression and survival in a rat model of hepatocellular carcinoma with liver cirrhosis. Cancer Chemother Pharmacol. 2010 May;65(6):1029–1037.
   PubMed Web of Science ®Google Scholar
• Jang JW, Park ST, Kwon JH, et al. Suppression of hepatic tumor growth and metastasis by metronomic therapy in a rat model of hepatocellular carcinoma. Exp Mol Med. 2011 May;43(5):305–312.
   PubMed Web of Science ®Google Scholar
• Martin-Padura I, Marighetti P, Agliano A, et al. Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Lab Invest. 2012 Jul;92(7):952–966.
   PubMed Web of Science ®Google Scholar
• Tang TC, Man S, Xu P, et al. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia. 2010 Nov;12(11):928–940.
   PubMed Web of Science ®Google Scholar
• Zhou F, Hu J, Shao JH, et al. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts. J Cancer Res Clin Oncol. 2012 Nov;138(11):1879–1890.
   PubMed Web of Science ®Google Scholar
• Treiber G, Wex T, Malfertheiner P. Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer. J Cancer Res Clin Oncol. 2009 Feb;135(2):271–281.
   PubMed Web of Science ®Google Scholar
• Brandi G, De Rosa F, Agostini V, et al. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study. Oncologist. 2013;18(12):1256–1257.
   PubMed Web of Science ®Google Scholar
• Trevisani F, Brandi G, Garuti F, et al. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation. J Cancer Res Clin Oncol. 2018 Feb;144(2):403–414.
   PubMed Web of Science ®Google Scholar
• Casadei Gardini A, Foca F, Scartozzi M, et al. Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. Sci Rep. 2017;7:42499.
   PubMed Web of Science ®Google Scholar
• Ravaioli M, Cucchetti A, Pinna AD, et al. The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation. Sci Rep. 2017 Sep;7(1):11305.
   PubMedGoogle Scholar
• Khedr GAE, Elzawawy SF, Gowil AG, et al. Metronomic capecitabine versus doxorubicin in advanced hepatocellular carcinoma. Korean J Clin Oncol. 2016;12(1):32–40.
   Google Scholar
• Mateen A, Adil AR. Role of metronomic capecitabine in advanced hepatocellular carcinoma. J Clin Oncol. 2014;32(15_suppl):e15119–e15119.
   Web of Science ®Google Scholar
• Hsu CH, Yang TS, Hsu C, et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer. 2010 Mar;102(6):981–986.
   PubMed Web of Science ®Google Scholar
• Shao YY, Lin ZZ, Hsu C, et al. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma. Oncology. 2012;82(1):59–66.
   PubMed Web of Science ®Google Scholar
• Hsu CH, Shen YC, Lin ZZ, et al. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol. 2010 Jul;53(1):126–131.
   PubMed Web of Science ®Google Scholar
• Walter I, Schulz U, Vogelhuber M, et al. Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial. Med Oncol. 2017 Nov;34(12):192.
   PubMed Web of Science ®Google Scholar
• Yang H, Woo HY, Lee SK, et al. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. Clin Mol Hepatol. 2017 Jun;23(2):128–137.
   PubMed Web of Science ®Google Scholar
• Woo HY, Youn JM, Bae SH, et al. Efficacy and safety of metronomic chemotherapy for patients with advanced primary hepatocellular carcinoma with major portal vein tumor thrombosis. Korean J Hepatol. 2012 Mar;18(1):32–40.
   PubMedGoogle Scholar
• Wang-Yuan Z, Jiang-Zheng Z, Lu YD, et al. Clinical efficacy of metronomic chemotherapy after cool-tip radiofrequency ablation in the treatment of hepatocellular carcinoma. Int J Hyperthermia. 2016;32(2):193–198.
   PubMed Web of Science ®Google Scholar
• Ueshima K, Kudo M, Tanaka M, et al. Phase I/II study of sorafenib in combination with hepatic arterial infusion chemotherapy using low-dose cisplatin and 5-fluorouracil. Liver Cancer. 2015 Dec;4(4):263–273.
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010 Apr;362(14):1273–1281.
   PubMed Web of Science ®Google Scholar
• Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010 Aug;103(4):469–474.
   PubMed Web of Science ®Google Scholar
• Walter T, Horgan AM, McNamara M, et al. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer. 2013 Jan;49(2):329–335.
   PubMed Web of Science ®Google Scholar
• Fornaro L, Cereda S, Aprile G, et al. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. Br J Cancer. 2014 Apr;110(9):2165–2169.
   PubMed Web of Science ®Google Scholar
• Cadamuro M, Spagnuolo G, Sambado L, et al. Low-dose paclitaxel reduces S100A4 nuclear import to inhibit invasion and hematogenous metastasis of cholangiocarcinoma. Cancer Res. 2016 Aug;76(16):4775–4784.
   PubMed Web of Science ®Google Scholar
• Hirose A, Tajima H, Ohta T, et al. Low-dose paclitaxel inhibits the induction of epidermal-mesenchymal transition in the human cholangiocarcinoma CCKS-1 cell line. Oncol Lett. 2013 Oct;6(4):915–920.
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhong DW, Wang QW, et al. Paclitaxel ameliorates fibrosis in hepatic stellate cells via inhibition of TGF-beta/Smad activity. World J Gastroenterol. 2010 Jul;16(26):3330–3334.
   PubMed Web of Science ®Google Scholar
• Zhang D, Sun L, Xian W, et al. Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-beta/Smad activity. Lab Invest. 2010 Mar;90(3):436–447.
   PubMed Web of Science ®Google Scholar
• Tajima H, Ohta T, Shinbashi H, et al. Phase I study of weekly palliative chemotherapy with low-dose third-line paclitaxel for biliary tract cancer. Mol Clin Oncol. 2017 May;6(5):753–757.
   PubMed Web of Science ®Google Scholar
• Aktas SH, Akbulut H, Akgun N, et al. Low dose chemotherapeutic drugs without overt cytotoxic effects decrease the secretion of VEGF by cultured human tumor cells: a tentative relationship between drug type and tumor cell type response. Cancer Biomark. 2012–2013;12(3):135–140.
   PubMed Web of Science ®Google Scholar
• Bocci G, Kerbel RS. Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol. 2016 Nov;13(11):659–673.
   PubMed Web of Science ®Google Scholar
• Di Desidero T, Orlandi P, Fioravanti A, et al. Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. Invest New Drugs. 2018 Aug;36(4):709–714.
   PubMed Web of Science ®Google Scholar
• Rochlitz C, Bigler M, von Moos R, et al. SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer – a multicenter, randomized phase III trial. BMC Cancer. 2016 Oct;16(1):780.
   PubMedGoogle Scholar
• Petrioli R, Pascucci A, Francini E, et al. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the multidisciplinary oncology group on gastrointestinal tumors. Anticancer Drugs. 2008 Jan;19(1):91–96.
   PubMed Web of Science ®Google Scholar
• André N, Banavali S, Snihur Y, et al. Has the time come for metronomics in low-income and middle-income countries? Lancet Oncol. 2013 May;14(6):e239–e248.
   PubMed Web of Science ®Google Scholar
• Abu Lila AS, Ishida T. Metronomic chemotherapy and nanocarrier platforms. Cancer Lett. 2017 Aug;400:232–242.
   PubMed Web of Science ®Google Scholar